Axovant to Present at Two Upcoming Investor Conferences
BASEL, Switzerland, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September 27, 2018 at 9:45 a.m. ET. Additionally, Dr. Cheruvu will participate in a fireside chat at the Chardan Annual Genetic Medicines Conference 2018 on October 9, 2018 at 3:15 p.m. ET.
A live webcast will be available for each conference in the Events section of Axovant's website at www.axovant.com. A replay will be available for 30 days following each conference.
About Axovant Sciences
Axovant is a clinical-stage neurological gene therapy company focused on developing a pipeline of clinical and nonclinical product candidates for debilitating diseases such as Parkinson's disease, oculopharyngeal muscular dystrophy, ALS, frontotemporal dementia, and other indications. Axovant is also developing small molecules for the treatment of Lewy body dementia and other neurology and psychiatry indications. For more information, visit www.axovant.com.
Contacts:
Investors
Tricia Truehart
(631) 892-7014
investors@axovant.com
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
